The phase Ib/II trial, which followed 33 patients for a median of 21.5 months, highlights how targeting the FAK-YAP signaling pathway can overcome the adaptive resistance that often renders KRAS G12C monotherapies less effective. Among the participants, 27 achieved a response, with the median duration of response currently not reached. The regimen notably extended median progression-free survival to 22.3 months, with a median overall survival of 27.8 months.
InxMed’s FAK Inhibitor Shows Potential in First-Line Lung Cancer Trial
A new clinical study published in The Lancet Respiratory Medicine reveals that combining the FAK inhibitor ifebemtinib with the KRAS G12C inhibitor garsorasib yields an 82% objective response rate in first-line non-small cell lung cancer patients, marking a significant advancement in chemotherapy-free treatment for patients with this specific mutation.
Dr. Zaiqi Wang, CEO of InxMed, noted that the combination blocks the adaptive resistance pathways typically triggered by KRAS inhibition. Safety data remains encouraging; while all patients experienced treatment-emergent adverse events, most were mild, and no treatment-related deaths were reported. This chemotherapy-free, all-oral approach is now being validated in a randomized phase III confirmatory trial, aiming to establish a new standard of care for the 12-14% of non-small cell lung cancer cases involving the KRAS G12C mutation.
Comments (0)
No comments yet. Be the first!